Marked car trial#

Methods and Results : A 46-y-old male with germinal center DLBCL without Myc, Bcl-2, or Bcl-6 translocations and with markedly positive PD-L1 expression had lymphoma refractory to R-CHOP, R-ICE, and R-DHAP and was enrolled in ZUMA-1. Here we report a case of a pt with rapidly progressing refractory DLBCL whose disease did not respond to axi-cel, who then went on to receive the anti-PD-1 monoclonal antibody nivolumab (nivo) off-study and experienced rapid tumor regression. Thus, there is a strong scientific rationale and significant clinical interest in exploring the role of immune checkpoint inhibitors to augment anti-tumor responses of axi-cel. #2042) and checkpoint genes, including programmed cell death-ligand 1 (PD-L1), may be upregulated in the tumor tissue of pts treated with axi-cel (Galon et al.

Programmed cell death-1 (PD-1) is expressed on antigen-activated CAR T cells (Perez et al. Grade ≥ 3 cytokine release syndrome (CRS) and neurologic events (NE) occurred in 13% and 28% of pts, respectively. At the primary analysis, the objective response rate was 82% with a 54% complete response rate 44% had ongoing responses (Locke et al.

Marked car trial#

Background : ZUMA-1 is a pivotal, multicenter trial of axi-cel, an autologous anti-CD19 CAR T therapy, for the treatment of patients (pts) with refractory, aggressive non-Hodgkin lymphoma.